The Anglonordic Life Science Conference is a great opportunity to discover, collaborate and invest in the fast growing Anglo-Nordic life science region.
The Conference, entering its 12th year, will be held on 23 April at the 1VS Westminster Conference Center in London UK. In order to increase the network possibilities and make the conference more productive, the Anglonordic Biotech Conference has this year been merged with the Anglonordic Medtech Conference and has a new name, from the Anglonordic Life Science Conference XII. Besides the biotech area and the medtech area, the conference includes a one-to-one meeting area, an exhibition area and a sponsor and lounge area.
Highlights of the biotech program include an interview with special guest speaker Susan Herbert, Executive Vice President and Global Business Development and Strategy at Merck Serono, who will talk about their global strategy. Martin Pule, CSO of Autolus, a University College London spinout, will present T-cell engineering for cancer applications, chimeric antigen receptors and beyond. Highlights of the medtech program include a keynote speech by Amir Babaei-Mahani, Senior Director External Innovation & Enabling Technologies at DePuy Synthes, who will talk about collaboration to drive medical device innovation. In addition, Rainer Christine, Partner at Earlybird will provide an update on the investment status in the medtech industry.
This year’s guest country will be Spain, who will participate with a delegation of research and development companies and investment firms. A reception to welcome delegates will also be held on the evening of 22 April 2015 at the Spanish Ambassador’s Residence in London. In the last few years Spain’s biotech and pharma industries have developed significantly. There are strong scientific and technological capabilities on which a globally competitive biopharmaceutical industry is being consolidated. The country is placed 10th in the world in terms of scientific power and 5th by scientific production in EU15 in 2013. The Spanish government also offers a strong support through low-interest credits and incentives during the start-up and growth phases of life science companies. There is an excellent infrastructure for innovation, showing an exponential growth of science and technology parks, research centers and institutes of technology. All of this makes Spain very attractive to international companies looking to expand their businesses and to set up scientific and technological alliances with Spanish companies and institutions.
Read more about the event: www.anglonordiclifescience.com
